showed a trendp = 0.017
9 Elderly patients with major depression have a poorer prognosis, are less responsive to treatment, and show greater functional decline compared with younger patients, highlighting the need for effective treatment; in this phase 3 double-blind study, esketamine nasal spray combined with a new oral antidepressant showed a trend toward improved efficacy in patients aged 65–74 years (p = 0.017) but not in those aged ≥75 years (p = 0.930), with continued improvement observed in the long-term open-label study. 2 Patients with treatment-resistant depression (TRD) have higher relapse rates and decreased daily functioning, and i